New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
07:47 EDTPFE, JECJacobs Engineering announces collaboration with Pfizer
Jacobs Engineering Group (JEC) announced a collaboration with Pfizer (PFE) on a modular process system to address the rapidly changing requirements of localized pharmaceutical manufacturing in emerging market countries. The collaboration brings together Pfizer’s aseptic drug product process expertise and Jacobs’ capabilities in modular engineering, fabrication, and testing to create a Rapid Deployment Module that integrates modular equipment, fully-automated control systems and single-use technology for bags, mixers, sterile connectors, manifolds and filters. The production systems are currently in their final stages of validation at a number of local pharmaceutical manufacturing sites around the world.
News For JEC;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
11:09 EDTJECJacobs Engineering sees Q1 typically lower than Q4
Comments made on Q4 earnings conference call.
08:33 EDTPFEPfizer announces availability of Trumenba vaccine
Pfizer announced hat TRUMENBA, the first and only FDA-approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is now available for order by healthcare providers in the United States.
07:29 EDTPFEPfizer less likely to pursue AstraZeneca after PD-L1 deal, says JPMorgan
Subscribe for More Information
07:18 EDTPFEWoodford confident in Astra, sees 50% chance of new Pfizer bid, Reuters reports
Investment manager Neil Woodford of Woodford Investment Management said he now has an even stronger belief in AstraZeneca (AZN), citing the company's strong product pipeline, and put the chances of a new takeover bid from Pfizer (PFE) at 50/50, reported Reuters, citing a statement from Woodford. Reference Link
06:39 EDTPFEAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
05:24 EDTJECJacobs Engineering sees FY15 EPS $3.35-$3.85, consensus $3.76
Subscribe for More Information
05:23 EDTJECJacobs Engineering reports Q4 EPS 65c, consensus 86c
Reports Q4 revenue $3.2B, consensus $3.32B. Included in the company’s results for the quarter ended September 26, is an aggregate after-tax negative impact of $30.4M, or 23c per diluted share, related to restructuring efforts. Consolidated tax expense for Q4 was negatively impacted by the effects of changing tax rates relating to certain of the company's international pension plans. This impact was substantially offset by the positive effects relating to the reassessment of certain international tax exposures and the resulting reversal of approximately $4.0M of accrued interest expense.
November 17, 2014
15:16 EDTJECNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Agilent Technologies (A), consensus 89c; Jacobs Engineering (JEC), consensus 86c; Urban Outfitters (URBN), consensus 41c; Omega Protein (OME), consensus 30c.
14:27 EDTPFEPfizer volatility flat into investor meeting
Subscribe for More Information
14:02 EDTJECJacobs Engineering technical comments before earnings
The stock has underperformed in the prior three months, trading down 10%. The trend was decidedly bearish in the front half of the period, but since the market lows of mid-October has modified to a sideways consolidation. In a longer-term view the recent price action has been part of a much larger downtrend since price peaked in late 2013. There is a potential bearish flag when viewed on a 5-year graph, with the flag being formed by the recent price consolidation. On bearish news, a breakdown below the low of the flag at $47 would trigger the pattern. Downside potential if the pattern triggers and completes is to the $35 area. If the news is better than current bearish expectations would suggest, the key for price would be breaking out of the top of the flag at $49. If that happens the pattern would be voided. Additional upside objectives would be at $50.56, $51.65, and $53.28 depending on the degree of positive surprise.
09:42 EDTPFEPfizer to host investor day
Subscribe for More Information
09:22 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:13 EDTPFEPortola, Bristol-Myers, Pfizer announce results from Phase 3 ANNEXA-A studies
Subscribe for More Information
07:16 EDTPFEMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
06:43 EDTPFEAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 14, 2014
14:53 EDTPFECVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
08:46 EDTJECJacobs Engineering names Kevin Berryman as EVP, CFO
Subscribe for More Information
07:14 EDTPFEAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use